Refractory Multiple Myeloma - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB512251240

Publication Date:

December 10, 2024

Pages:

102

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Refractory Multiple Myeloma was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for Refractory Multiple Myeloma was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Refractory Multiple Myeloma was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for Refractory Multiple Myeloma was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of Refractory Multiple Myeloma include Bristol Myers Squibb, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Janssen Global Services, LLC, Gilead Sciences, Inc., Fresenius Kabi, GSK plc., Novartis AG and Takeda Pharmaceutical Company Limited, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Refractory Multiple Myeloma, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Refractory Multiple Myeloma by region & country, by Type, and by Application.
The Refractory Multiple Myeloma market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Refractory Multiple Myeloma.
Market Segmentation
By Company
Bristol Myers Squibb
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
Janssen Global Services, LLC
Gilead Sciences, Inc.
Fresenius Kabi
GSK plc.
Novartis AG
Takeda Pharmaceutical Company Limited
Genentech, Inc.
Segment by Type:
Proteosome Inhibitor
Immunomodulators
Anti-CD38 Monoclonal Antibody
Others
Segment by Application
Hospital
Specialty Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Refractory Multiple Myeloma manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Refractory Multiple Myeloma in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Refractory Multiple Myeloma in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Refractory Multiple Myeloma Product Introduction
1.2 Global Refractory Multiple Myeloma Market Size Forecast
1.3 Refractory Multiple Myeloma Market Trends & Drivers
1.3.1 Refractory Multiple Myeloma Industry Trends
1.3.2 Refractory Multiple Myeloma Market Drivers & Opportunity
1.3.3 Refractory Multiple Myeloma Market Challenges
1.3.4 Refractory Multiple Myeloma Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Refractory Multiple Myeloma Players Revenue Ranking (2023)
2.2 Global Refractory Multiple Myeloma Revenue by Company (2019-2024)
2.3 Key Companies Refractory Multiple Myeloma Manufacturing Base Distribution and Headquarters
2.4 Key Companies Refractory Multiple Myeloma Product Offered
2.5 Key Companies Time to Begin Mass Production of Refractory Multiple Myeloma
2.6 Refractory Multiple Myeloma Market Competitive Analysis
2.6.1 Refractory Multiple Myeloma Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Refractory Multiple Myeloma Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Refractory Multiple Myeloma as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Proteosome Inhibitor
3.1.2 Immunomodulators
3.1.3 Anti-CD38 Monoclonal Antibody
3.1.4 Others
3.2 Global Refractory Multiple Myeloma Sales Value by Type
3.2.1 Global Refractory Multiple Myeloma Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Refractory Multiple Myeloma Sales Value, by Type (2019-2030)
3.2.3 Global Refractory Multiple Myeloma Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospital
4.1.2 Specialty Clinic
4.1.3 Others
4.2 Global Refractory Multiple Myeloma Sales Value by Application
4.2.1 Global Refractory Multiple Myeloma Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Refractory Multiple Myeloma Sales Value, by Application (2019-2030)
4.2.3 Global Refractory Multiple Myeloma Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Refractory Multiple Myeloma Sales Value by Region
5.1.1 Global Refractory Multiple Myeloma Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Refractory Multiple Myeloma Sales Value by Region (2019-2024)
5.1.3 Global Refractory Multiple Myeloma Sales Value by Region (2025-2030)
5.1.4 Global Refractory Multiple Myeloma Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Refractory Multiple Myeloma Sales Value, 2019-2030
5.2.2 North America Refractory Multiple Myeloma Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Refractory Multiple Myeloma Sales Value, 2019-2030
5.3.2 Europe Refractory Multiple Myeloma Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Refractory Multiple Myeloma Sales Value, 2019-2030
5.4.2 Asia Pacific Refractory Multiple Myeloma Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Refractory Multiple Myeloma Sales Value, 2019-2030
5.5.2 South America Refractory Multiple Myeloma Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Refractory Multiple Myeloma Sales Value, 2019-2030
5.6.2 Middle East & Africa Refractory Multiple Myeloma Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Refractory Multiple Myeloma Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Refractory Multiple Myeloma Sales Value
6.3 United States
6.3.1 United States Refractory Multiple Myeloma Sales Value, 2019-2030
6.3.2 United States Refractory Multiple Myeloma Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Refractory Multiple Myeloma Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Refractory Multiple Myeloma Sales Value, 2019-2030
6.4.2 Europe Refractory Multiple Myeloma Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Refractory Multiple Myeloma Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Refractory Multiple Myeloma Sales Value, 2019-2030
6.5.2 China Refractory Multiple Myeloma Sales Value by Type (%), 2023 VS 2030
6.5.3 China Refractory Multiple Myeloma Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Refractory Multiple Myeloma Sales Value, 2019-2030
6.6.2 Japan Refractory Multiple Myeloma Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Refractory Multiple Myeloma Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Refractory Multiple Myeloma Sales Value, 2019-2030
6.7.2 South Korea Refractory Multiple Myeloma Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Refractory Multiple Myeloma Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Refractory Multiple Myeloma Sales Value, 2019-2030
6.8.2 Southeast Asia Refractory Multiple Myeloma Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Refractory Multiple Myeloma Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Refractory Multiple Myeloma Sales Value, 2019-2030
6.9.2 India Refractory Multiple Myeloma Sales Value by Type (%), 2023 VS 2030
6.9.3 India Refractory Multiple Myeloma Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Bristol Myers Squibb
7.1.1 Bristol Myers Squibb Profile
7.1.2 Bristol Myers Squibb Main Business
7.1.3 Bristol Myers Squibb Refractory Multiple Myeloma Products, Services and Solutions
7.1.4 Bristol Myers Squibb Refractory Multiple Myeloma Revenue (US$ Million) & (2019-2024)
7.1.5 Bristol Myers Squibb Recent Developments
7.2 Teva Pharmaceutical Industries Ltd.
7.2.1 Teva Pharmaceutical Industries Ltd. Profile
7.2.2 Teva Pharmaceutical Industries Ltd. Main Business
7.2.3 Teva Pharmaceutical Industries Ltd. Refractory Multiple Myeloma Products, Services and Solutions
7.2.4 Teva Pharmaceutical Industries Ltd. Refractory Multiple Myeloma Revenue (US$ Million) & (2019-2024)
7.2.5 Teva Pharmaceutical Industries Ltd. Recent Developments
7.3 Pfizer Inc.
7.3.1 Pfizer Inc. Profile
7.3.2 Pfizer Inc. Main Business
7.3.3 Pfizer Inc. Refractory Multiple Myeloma Products, Services and Solutions
7.3.4 Pfizer Inc. Refractory Multiple Myeloma Revenue (US$ Million) & (2019-2024)
7.3.5 Janssen Global Services, LLC Recent Developments
7.4 Janssen Global Services, LLC
7.4.1 Janssen Global Services, LLC Profile
7.4.2 Janssen Global Services, LLC Main Business
7.4.3 Janssen Global Services, LLC Refractory Multiple Myeloma Products, Services and Solutions
7.4.4 Janssen Global Services, LLC Refractory Multiple Myeloma Revenue (US$ Million) & (2019-2024)
7.4.5 Janssen Global Services, LLC Recent Developments
7.5 Gilead Sciences, Inc.
7.5.1 Gilead Sciences, Inc. Profile
7.5.2 Gilead Sciences, Inc. Main Business
7.5.3 Gilead Sciences, Inc. Refractory Multiple Myeloma Products, Services and Solutions
7.5.4 Gilead Sciences, Inc. Refractory Multiple Myeloma Revenue (US$ Million) & (2019-2024)
7.5.5 Gilead Sciences, Inc. Recent Developments
7.6 Fresenius Kabi
7.6.1 Fresenius Kabi Profile
7.6.2 Fresenius Kabi Main Business
7.6.3 Fresenius Kabi Refractory Multiple Myeloma Products, Services and Solutions
7.6.4 Fresenius Kabi Refractory Multiple Myeloma Revenue (US$ Million) & (2019-2024)
7.6.5 Fresenius Kabi Recent Developments
7.7 GSK plc.
7.7.1 GSK plc. Profile
7.7.2 GSK plc. Main Business
7.7.3 GSK plc. Refractory Multiple Myeloma Products, Services and Solutions
7.7.4 GSK plc. Refractory Multiple Myeloma Revenue (US$ Million) & (2019-2024)
7.7.5 GSK plc. Recent Developments
7.8 Novartis AG
7.8.1 Novartis AG Profile
7.8.2 Novartis AG Main Business
7.8.3 Novartis AG Refractory Multiple Myeloma Products, Services and Solutions
7.8.4 Novartis AG Refractory Multiple Myeloma Revenue (US$ Million) & (2019-2024)
7.8.5 Novartis AG Recent Developments
7.9 Takeda Pharmaceutical Company Limited
7.9.1 Takeda Pharmaceutical Company Limited Profile
7.9.2 Takeda Pharmaceutical Company Limited Main Business
7.9.3 Takeda Pharmaceutical Company Limited Refractory Multiple Myeloma Products, Services and Solutions
7.9.4 Takeda Pharmaceutical Company Limited Refractory Multiple Myeloma Revenue (US$ Million) & (2019-2024)
7.9.5 Takeda Pharmaceutical Company Limited Recent Developments
7.10 Genentech, Inc.
7.10.1 Genentech, Inc. Profile
7.10.2 Genentech, Inc. Main Business
7.10.3 Genentech, Inc. Refractory Multiple Myeloma Products, Services and Solutions
7.10.4 Genentech, Inc. Refractory Multiple Myeloma Revenue (US$ Million) & (2019-2024)
7.10.5 Genentech, Inc. Recent Developments
8 Industry Chain Analysis
8.1 Refractory Multiple Myeloma Industrial Chain
8.2 Refractory Multiple Myeloma Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Refractory Multiple Myeloma Sales Model
8.5.2 Sales Channel
8.5.3 Refractory Multiple Myeloma Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Bristol Myers Squibb
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
Janssen Global Services, LLC
Gilead Sciences, Inc.
Fresenius Kabi
GSK plc.
Novartis AG
Takeda Pharmaceutical Company Limited
Genentech, Inc.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂